## INCY: Incyte Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.13 indicates fundamental undervaluation. Quality metrics strong (ROE 30%, ROA 14%). Consistent execution (3/4 quarters beat estimates). Caution: declining volume (53% of avg).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($93.37)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 4
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Incyte Takes JPMorgan Stage as Investors Look for Pipeline Signals**
- Source: MyChesCo | 20251229T130749 | Somewhat-Bullish | Relevance: 100%
- Incyte (Nasdaq: INCY) is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. This presentation is a significant event for investors, who will be closely observing developments in the company's oncology and inflammation and autoimmunity pipeline. The conference serves as a key forum for biopharmaceutical companies to outline clinical progress and strategic priorities.

**2. Europe Approves Incyteâ€™s Dual-Target Lymphoma Therapy, Expanding Options**
- Source: MyChesCo | 20251229T050828 | Bullish | Relevance: 100%
- The European Commission has approved Incyte's (Nasdaq: INCY) Minjuvi (tafasitamab) for use in combination with lenalidomide and rituximab for adult patients with relapsed or refractory follicular lymphoma. This approval introduces the first CD19- and CD20-dual-targeted, chemotherapy-free immunotherapy regimen for this patient population in Europe, providing a new option for patients with limited treatment choices. The decision was based on the Phase 3 inMIND trial, which demonstrated a statistically significant improvement in progression-free survival for patients receiving the Minjuvi combination.

**3. 22,200 Shares in Incyte Corporation $INCY Purchased by Burney Co.**
- Source: MarketBeat | 20251228T110827 | Bullish | Relevance: 100%
- Burney Co. recently purchased 22,200 shares of Incyte Corporation (NASDAQ:INCY) in Q3, valued at approximately $1.883 million, contributing to institutional investors owning 96.97% of the stock. Meanwhile, insiders sold 88,318 shares totalling $8.71 million over the last quarter. Analysts currently maintain a "Hold" rating with an average target price of $99.79 for Incyte, which recently exceeded EPS and revenue estimates.

**4. Cwm LLC Buys 65,292 Shares of Incyte Corporation $INCY**
- Source: MarketBeat | 20251228T090423 | Bullish | Relevance: 100%
- Cwm LLC increased its stake in Incyte Corporation (NASDAQ: INCY) by 49.8% in Q3, acquiring 65,292 shares to hold a total of 196,472 shares valued at approximately $16.66 million. Incyte recently outperformed earnings expectations, reporting an EPS of $2.26 against an anticipated $1.65, and revenues of $1.37 billion. Despite a consensus "Hold" rating from analysts, several firms have raised their price targets for the biopharmaceutical company.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 3, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Morgan Stanley | $92 | $86 | +7% |
| 2025-12-08 | Wells Fargo | $116 | $97 | +20% |
| 2025-12-08 | Mizuho | $121 | $90 | +34% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Morgan Stanley | main | Equal-Weight |
| 2025-12-08 | Wells Fargo | main | Overweight |
| 2025-12-08 | Mizuho | up | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 18 ($25.63M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 59.2% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 5 |

**Top Holders:**
- Baker Bros. Advisors: 15.7% (0.0%)
- Vanguard Group Inc: 10.2% (-0.9%)
- Blackrock Inc.: 9.1% (-0.3%)
- Dodge & Cox Inc.: 7.1% (-4.5%)
- State Street Corpora: 4.9% (-2.0%)

### Key Risks

1. Heavy insider selling: $26M sold (18 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 3 raises (avg +20%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.13 indicates undervaluation relative to growth. Forward P/E 12.9x attractive for 14% earnings growth. Quality metrics strong (ROE 30%, ROA 14%, margin 25%). Balance sheet: strong liquidity (3.2x), low leverage (D/E 0.36). Analyst sentiment positive (3 raises, avg +20%). Insider selling cluster ($25.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $19.4B |
| Beta | 0.81 |
| 52W Range | $53.56 - $109.28 |
| Short Interest | 7.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.13 |
| Forward P/E | 12.9 |
| Current P/E | 14.7 |
| YoY Growth | 13.7% |
| EPS Direction | RISING |

### Technicals

MRS_20 stable at -0.1% (minimal 5-day change). Below STRENGTH zone by 4.1pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.26x) but short-term weakness (below SMA20). RSI neutral at 48. Volume at 53% of 20MA suggests lack of conviction. OFD pattern: -SLL (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.13% (CS: 42) | Neutral |
| RSI_14 | 48.5 | Neutral |
| MACD Histogram | 0.03 | Bullish |
| vs SMA20 | 1.000x | Below |
| vs SMA50 | 0.995x | Below |
| vs SMA200 | 1.256x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $98.91
- **Stop Loss:** $93.37 (5.6% risk)
- **Target:** $109.99 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 238
- **Position Value:** $23,540.58
- **Portfolio %:** 23.54%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (HIGH) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with balanced risk signals and moderate market participation. VIX at 14.33 indicates calm conditions, while positive yield curve (+59bps) and stable economic data support continued expansion. Year-end positioning and Fed uncertainty create near-term caution, but no systemic risks evident.*

### Earnings

**Next:** 2026-02-09 (Est: $1.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.64 | $2.26 | +38.0% |
| 2025Q2 | $1.47 | $1.57 | +6.6% |
| 2025Q1 | $1.03 | $1.16 | +12.3% |
| 2024Q4 | $1.55 | $1.43 | -8.0% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*